TY  - CONF

T1  - Serum concentrations of AMG 162 were maintained and bone resorption was suppressed for 3 months following a single subcutaneous dose in patients with breast cancer-related bone metastases

JO  - JOURNAL OF BONE AND MINERAL RESEARCH

PY  - 2004/09/01

AU  - Peterson MC

AU  - Martin SW

AU  - Stouch BJ

AU  - Chen D

AU  - Bauhman S

AU  - Holloway DL

AU  - Rasmussen AS

AU  - Lipton A

AU  - Coleman R

AU  - Body JJ

AU  - Bekker PJ et al

ED  - 

VL  - 19

IS  - 9

SP  - 1595

EP  - 1595

Y2  - 2025/10/10

ER  -